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Abstract
Introduction: In 2015, the World Health Organization recommended that all HIV-infected individuals consider ART initiation
as soon as possible after diagnosis. Sex differences in choice of initial ART regimen, indications for switching, time to switching
and choice of second-line regimens have not been well described. The aims of this study were to describe first-line ART and
CD4 count at ART initiation by sex, calendar year and region, and to analyse time to change or interruption in first-line ART,
according to sex in each region.
Methods: Participating cohorts included: Southern, East and West Africa (IeDEA-Africa), North America (NA-ACCORD), Carib-
bean, Central/South America (CCASAnet) and Asia-Pacific including Australia (IeDEA Asia-Pacific). The primary outcomes anal-
ysed for each region and according to sex were choice of initial ART, time to switching and time to discontinuation of the
first-line regimen.
Results and Discussion: The combined cohort data set comprised of 715,252 participants across seven regions from low- to
high-income settings. The median CD4 count at treatment initiation was lower in men compared with women in nearly all
regions and time periods. Women from North America and Southern Africa were more likely to switch ART compared to men
(p < 0.001) with approximately 90% of women reporting a major change after 10 years in North America. Overall, after
8 years on ART, >50% of HIV- positive men and women from Southern Africa, East Africa, South and Central America
remained on their original regimen. Men were more likely to have a treatment interruption compared with women in low- and
middle-income countries from the Asia/Pacific region (p < 0.001) as were men from Southern Africa (p < 0.001). Greater than
75% of men and women did not report a treatment interruption after 10 years on ART from all regions except North America
and Southern Africa.
Conclusions: There are regional variations in the ART regimen commenced at baseline and rates of major change and treat-
ment interruption according to sex. Some of this is likely to reflect changes in local and international antiretroviral guideline
recommendations but other sex-specific factors such as pregnancy may contribute to these differences.
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1 | INTRODUCTION
Over the past decade, HIV treatment guidelines have changed,
with the CD4+ count threshold for initiating antiretroviral ther-
apy (ART) gradually increasing from less than 350 cells/lL in
2010 to <500 cells/lL in 2013 [1]. In 2014, UNAIDS launched
the “90-90-90” goals to increase to 90% by 2020 the propor-
tion of persons living with HIV infection who know their status,
the proportion of persons living with HIV infection receiving
ART and the proportion of persons living with HIV infection on
ART who have achieved viral suppression [2]. More recently, in
September 2015, the World Health Organization (WHO)
announced that all persons infected with HIV should begin
ART as soon as possible after diagnosis, thereby removing eligi-
bility criteria for all populations and age groups (www.who.int).
Accompanying these recommendations, expanded ART pro-
grammes and wider availability of virological monitoring [3]
are making quality care more accessible globally, including
lower income countries. It can be anticipated that earlier
treatment initiation and wider access to ART will decrease
HIV-related mortality further and result in an ever increasing
number of people starting and remaining on lifelong ART.
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With expanded virological monitoring, the number of individu-
als diagnosed with treatment failure and in need of more
costly second-line regimens will present new challenges. Other
indications for switching ART may include toxicity, the poten-
tial for significant drug-drug interactions such as when starting
tuberculosis therapy, and pregnancy. Durability, particularly of
first-line regimens, is central to the sustainability of treatment
programmes. Therefore, attention should be focused on
understanding the factors that influence initial regimen choice,
potentially harmful treatment interruptions, and the use of
costly second- and third-line regimens.
Patient sex is known to influence antiretroviral treatment
decisions. However to date, sex differences in choice of initial
regimen, indications for switching, time to switching and choice
of second-line regimens have not been well described. Both
males and females, bring unique biological, psychological and
social characteristics, which may influence the manifestations of
HIV infection and clinical management. Previous analyses have
reported that compared to men, women are less likely to have
advanced disease and more likely to have a higher CD4 count at
ART initiation, and are less likely to be lost to follow-up [4-6].
Sex differences in choice of initial regimen may be influenced by
factors such as local guidelines, drug availability, drug interac-
tions, potential toxicity, pregnancy and pre-conceptual planning.
Similarly, indications for switching may include sex-specific
events such as pregnancy. Early modification of an initial ART
regimen has been associated with poor clinical outcomes [7].
While the frequency and reasons for change in therapy has been
assessed in cohort studies from diverse settings including
resource-rich and -limited settings, the differences between men
and women have not been comprehensively reported. [8-12].
Findings from the limited number of studies of sex differences
suggest that reasons for ART interruption, choice of regimen
and risk of toxicity vary between men and women. In a study
from Asia [13], significant differences in choice of initial regimen
were reported with more females receiving non-nucleoside
reverse transcriptase inhibitor (NNRTI)-based combinations.
Women were also more likely to change the treatment due to
toxicity and side effects. Gender differences in toxicity have
been reported for nucleoside analogues [14], NNRTIs [15] and
protease inhibitors (PI) [16], though clinical trials have not been
able to definitively establish sex differences in toxicity risk. Clini-
cal outcomes such as immunological response, new AIDS events,
or death, have not been found to significantly differ by sex in
either resource-rich [17-19] or -limited settings [13].
The primary aim of this study was to describe first-line ART
and CD4 count at ART initiation by sex, time and region. The
secondary aim of this study was to analyse time to major
change in first-line ART and time to major interruption in
first-line ART by sex in each region. Particularly in resource-
limited settings, with restricted access to second- and third-
line agents, better understanding of time to switching and
indications for switching is important for maximizing treatment
durability and improving the outcomes.
2 | METHODS
2.1 | Participants and settings
The International epidemiology Databases to Evaluate AIDS
(IeDEA) is a collaborative network of ART programmes with
sites in various regions throughout the world. Key clinical data
are collected and collated within IeDEA generating large data
sets to address high-priority HIV research questions. Partici-
pating cohorts include: Southern, East and West Africa
(IeDEA-Africa), North America (NA-ACCORD), Caribbean,
Central/South America (CCASAnet), and Asia-Pacific including
Australia (IeDEA Asia-Pacific). All participating cohorts
obtained local ethical committee approval to contribute data
to the IeDEA collaboration. Countries were characterized as
high, middle or low-income countries based on standard defi-
nitions using the gross national income per capita.
2.2 | Outcomes
The primary outcomes analysed for each region and according
to sex were choice of initial antiretroviral regimen, time to
switching and time to interruption of the first-line regimen.
2.3 | Inclusion criteria and definitions
Patients aged 18 years or older with a known date of ART ini-
tiation and a known first-line regimen who had not previously
received ART (with the exception of ART used only for pre-
vention of mother-to-child transmission (PMTCT) were
included in the study for the period between 2003 and 2014.
All data were de-identified for analysis. A switch in ART was
defined as either a change in class of antiretrovirals or a
change of at least two agents. An interruption in ART was
defined as a documented treatment interruption (i.e. receipt
of no antiretrovirals) of at least 30 days. Loss to follow-up
(LTFU) was not considered as a treatment interruption in the
main analysis as LTFU could be due to multiple reasons such
as transfer out to other ART programmes, death or migration
and may not necessarily imply an interruption. However, rates
of LTFU (defined as no documented visit for at least twelve
months before the closing date of the database) were com-
pared by sex and region.
Patient level variables included sex, age, date of enrolment
in cohort, date of last clinic visit, date of death, date of trans-
fer, date of ART initiation, type of first-line regimen (EFV vs.
NVP vs. PI-based regimen) and type of nucleoside reverse
transcriptase inhibitor (NRTI) backbone (stavudine [d4T] vs.
zidovudine [AZT] vs. TDF vs. other NRTI backbone). Pregnancy
data were not routinely collected at all sites across the
time period of the study or available for inclusion in the final
analysis.
2.4 | Statistical analysis
Descriptive statistics were used to describe first-line ART and
CD4 count at ART initiation by sex, calendar year and region.
To analyse time to switching in first-line ART and time to
interruption in first-line ART by sex in each region, follow-up
time started at the date of ART initiation and ended at either
the first outcome or was censored at the end of available fol-
low-up. We also assessed whether there was an interaction
between region and sex variables. Cox regression models
were used to adjust for the following variables: age and CD4
count at ART initiation and mode of exposure (injecting drug
use vs. other) where available. Mode of exposure was only
available for NA-ACCORD, CCASAnet and IeDEA Asia-Pacific.
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Given the heterogeneity between regions, we present the
data individually by each region.
Two sensitivity analyses were performed: (i) excluding sites
for potential misclassification of treatment interruption
(namely two sites from Southern Africa as these sites pre-
populate their ART tables and could potentially record an “in-
terruption” due to recording error) and (ii) excluding women
aged <35 years to try and account for switching or interrup-
tion due to pregnancy. Change to a tenofovir (TDF)/lamivu-
dine or emtricitabine (XTC) + Efavirenz (EFV) regimen from
other NRTI and NNRTI regimens was not counted as a
change.
3 | RESULTS
The combined cohort data set for this study comprised of
715,252 participants across seven regions including both
low- and high-income settings. First-line ART varied accord-
ing to setting and sex, with changes over time (Table 1).
Efavirenz was more likely to be included in the first-line
regimen in men compared with women but the proportion
of women initiating efavirenz-based regimens increased in
many regions from 2010 onwards. Protease inhibitors were
rarely included in first-line regimens in low-income settings
compared to high-income settings for both men and
women.
More specifically, in the Asia-Pacific region (including low-,
middle- and high-income countries) nevirapine was the NNRTI
more commonly prescribed in the first ART regimen in the
earlier time period (2003 to 2005) for both men and women
but this declined in the later time period (2010 to 2014) with
efavirenz as the most commonly prescribed NNRTI. Not sur-
prisingly, the prescribing of a D4T/3TC backbone declined sig-
nificantly over time while TDF-containing regimens increased.
A similar pattern in NNRTI prescribing was seen in the South-
ern Africa and East Africa regions. In contrast, West Africa
had a relatively high proportion of clients started on efavirenz
across all time periods with little change in proportion of cli-
ents on nevirapine over time. And unlike other regions AZT/
3TC still remained the preferred NRTI backbone even for the
most recent time period (2010 to 2014) for both men and
women.
Compared to other regions North America used very little
nevirapine as the preferred NNRTI in the initial regimen irre-
spective of sex (<10% across all time periods) and used very
high levels of TDF (>80% in both men and women) in the
most recent time period (2010 to 2014). Finally the Carib-
bean, Central and South America reported consistently higher
use of efavirenz compared with nevirapine in men compared
with women across all time periods and similar to North
America, tenofovir inclusion in the initial regimen increased
from <3% in 2003 to 2005 to >40% in 2010 to 2014 in both
men and women.
The median CD4 count at ART initiation was, in all cases,
lower in men compared to women in each region and time
period with the exception of Asia-Pacific sites and North
America from 2010 onwards (Table 2).
The median age (IQR) at ART initiation was 35.0 years
(28.8 to 42.3). For men the median age (IQR) was 37.3 years
(31.1 to 44.6) and for women 33.4 years (27.7 to 40.4).
Women contributing data from North America and South-
ern Africa were more likely to have a switch in ART compared
to men (Figure 1). In North America, approximately 90% of
women had reported a major change in their ART regimen
after 10 years compared to closer to 75% of men (p < 0.01).
In Southern Africa, women were also more likely to have a
major change in the ART regimen (p < 0.01) but overall after
10 years just under 50% of both men and women were still
on their original regimens. Men were more likely to switch
ART in Asia/Pacific high-income countries and East Africa
(women were more likely to have a major switch in the first
8 years after treatment initiation, but men are more likely to
switch after 8 years, Figure 1). Differences were non-signifi-
cant from Caribbean, Central/South America, West Africa and
Asia/Pacific low-income countries.
Overall, 8 years after ART initiation, more than 50% of
HIV-positive males and females from Southern Africa, East
Africa, and South and Central America remained on their orig-
inal regimen without a switch. Males and females from low-
and middle-income countries in the Asia/Pacific region were
most likely to have had a switch with less than 25% still on
their original regimen (Figure 1). This was a similar finding in
women from North America with less than 25% on their origi-
nal regimen after 8 years. These differences occurred irre-
spective of low-, middle- or high-income status of the
countries contributing data from the region or the most com-
mon ART combination prescribed initially in the region.
In terms of treatment interruption there were no significant
differences according to sex in South and Central America,
West Africa (albeit very low rates of reported treatment inter-
ruption) and Asia Pacific (high income). In Asia/Pacific low- and
lower middle-income sites men were more likely to have a
treatment interruption compared with women (p < 0.001) as
were men in Southern Africa (p < 0.001). Women were more
likely to have a treatment interruption compared with males
in East Africa and North America (Figure 2). However, in all
regions except North America and Southern Africa, greater
than 75% of men and women did not report a treatment
interruption after 10 years of ART.
4 | DISCUSSION
Our key findings are that there are regional variations in
choice of initial ART regimen according to sex, and that the
relative contribution from different antiretroviral classes has
changed over time, which likely reflects changes in local, WHO
and other guidelines, and availability of individual drugs. Over-
all, women were more likely than men to switch their ART in
North America and Southern Africa and men were more likely
to have a treatment interruption in Asia/Pacific high-income
countries and in Southern Africa, although this varied consid-
erably across different regions. Other than in North America
and Southern Africa, more than 75% of HIV-infected individu-
als had not had a treatment interruption after 10 years irre-
spective of sex and choice of initial regimen.
We note that efavirenz was more likely to be included in
first-line ART for men compared to women across all regions
and all time periods. This likely reflects the historical concerns
regarding the potential teratogenicity of efavirenz and the
impact of local and international guidelines in place during the
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Table 1. First-line antiretroviral therapy according to region and sex over three time periods
Time period
First-line
ART regimen
2003 to 2005 2006 to 2009 2010 to 2014
Setting
Males
N (%)
Females
N(%)
Males
N (%)
Females
N(%)
Males
N (%)
Females
N(%)
Asia/Pacific Low/low
middle-income
settings
N = 17,282
EFV 511 (21.6) 134 (15.2) 2047 (48.4) 698 (29.7) 2699 (60.5) 1381 (45.7)
NVP 1667 (70.7) 642 (73.2) 2024 (47.9) 1427 (60.8) 1613 (36.2) 1463 (48.5)
PI 42 (1.7) 17 (1.9) 84 (2.0) 42 (1.8) 79 (1.8) 73 (2.4)
TDF 18 (0.8) 5 (0.6) 244 (5.8) 80 (3.4) 1717 (38.5) 1046 (34.7)
AZT/3TC 585 (24.8) 171 (19.5) 1559 (36.7) 616 (26.3) 1579 (35.4) 1064 (35.2)
D4T/3TC 1692 (71.8) 634 (72.3) 2321 (55.0) 1457 (62.1) 1031 (23.1) 736 (24.4)
Other NRTI
backbone
35 (1.5) 61 (6.7) 62 (1.5) 183 (7.8) 77 (1.7) 127 (4.2)
Asia/Pacific
Upper-middle/
high-income
settings
N = 7394
EFV 312 (35.7) 89 (20.2) 771 (40.8) 148 (24.5) 1366 (67.4) 148 (47.4)
NVP 268 (30.7) 264 (60.0) 851 (45.0) 385 (63.4) 267 (13.2) 104 (33.3)
PI 274 (31.2) 73 (16.6) 227 (12.0) 63 (10.4) 337 (16.6) 53 (17.0)
TDF 67 (7.7) 29 (6.6) 306 (16.2) 85 (14.1) 1020 (50.3) 113 (36.2)
AZT/3TC 282 (32.3) 74 (16.8) 703 (37.2) 166 (27.4) 411 (20.3) 69 (22.1)
D4T/3TC 374 (42.8) 290 (65.9) 705 (37.3) 332 (54.9) 174 (8.6) 87 (27.9)
Other NRTI
backbone
150 (17.2) 47 (10.7) 179 (9.5) 21 (3.5) 421 (20.8) 41 (13.1)
Southern
Africa N = 478,336
EFV 8576 (39.4) 8524 (28.0) 50,279 (52.9) 60,432 (40.2) 44,772 (68.8) 60,400 (52.7)
NVP 12,575 (57.8) 21,040 (69.0) 42,609 (44.8) 86,783 (57.7) 18,657 (28.7) 52,234 (45.5)
PI 630 (2.9) 1000 (3.3) 2269 (2.4) 3259 (2.2) 1542 (2.4) 2038 (1.8)
TDF 23 (0.1) 58 (0.2) 19,269 (20.3) 24,574 (16.4) 28,524 (43.8) 46,582 (40.6)
AZT/3TC 7684 (35.3) 7502 (24.6) 14,109 (14.9) 20,732 (13.8) 4623 (7.1) 11,442 (10.0)
D4T/3TC 13,915 (64.0) 22,779 (74.7) 60,353 (63.5) 102,806 (68.4) 18,328 (28.2) 30,054 (26.2)
Other NRTI
backbone
148 (0.7) 177 (0.6) 1,476 (1.6) 2403 (1.6) 13,660 (21.0) 26,725 (23.3)
East Africa N = 92,054 EFV 883 (21.2) 1105 (13.4) 4349 (25.3) 5338 (16.9) 4440 (44.4) 7516 (41.5)
NVP 3316 (79.6) 7115 (86.4) 12,893 (75.1) 25,818 (82.0) 5664 (56.6) 10,995 (60.7)
PI 0 (0) 0 (0) 2 (0.01) 571 (1.8) 0 (0) 11 (0.06)
TDF 42 (1.0) 102 (1.2) 281 (1.6) 455 (1.4) 3745 (37.4) 6680 (36.9)
AZT/3TC 404 (9.7) 620 (7.5) 5165 (30.1) 8598 (27.3) 4304 (43.0) 7636 (42.2)
D4T/3TC 3742 (89.8) 7775 (92.0) 11,780 (68.6) 22,550 (71.6) 1972 (19.7) 3839 (21.2)
Other NRTI
backbone
11 (0.3) 15 (0.2) 29 (0.2) 65 (0.2) 42 (0.4) 68 (0.4)
West Africa N = 52,123 EFV 2097 (46.2) 3285 (42.6) 4292 (45.1) 4623 (25.5) 1740 (45.8) 2305 (30.3)
NVP 1659 (36.5) 3403 (44.2) 4705 (49.4) 12,444 (68.6) 1762 (46.4) 4705 (61.8)
PI 637 (14.0) 804 (10.4) 452 (4.7) 850 (4.7) 260 (6.8) 491 (6.5)
TDF 56 (1.2) 82 (1.1) 1965 (20.6) 2905 (16.0) 1091 (28.7) 1825 (24.0)
AZT/3TC 1535 (33.8) 2251 (29.2) 3930 (41.2) 7357 (40.6) 1920 (50.5) 4124 (54.2)
D4T/3TC 2790 (61.4) 5149 (66.8) 3558 (37.4) 7707 (42.5) 659 (17.3) 1479 (19.4)
Other NRTI
backbone
195 (42.3) 268 (3.5) 150 (1.6) 275 (1.5) 140 (3.7) 211 (2.8)
North America,
N = 46,023
EFV 1959 (37.5) 543 (30.3) 3733 (45.8) 844 (32.0) 2834 (47.4) 467 (30.7)
NVP 358 (6.9) 157 (8.8) 271 (3.3) 93 (3.5) 149 (2.5) 44 (2.9)
PI 2728 (52.3) 982 (54.7) 3989 (48.9) 1629 (61.8) 2492 (41.7) 846 (55.7)
TDF 2485 (47.6) 730 (40.7) 6401 (78.5) 1787 (67.8) 5320 (88.9) 1216 (80.1)
AZT/3TC 1,994 (38.2) 834 (46.5) 788 (9.7) 518 (19.7) 199 (3.3) 170 (11.2)
D4T/3TC 400 (7.7) 145 (8.1) 79 (1.0) 30 (1.1) 16 (0.3) 4 (0.3)
Other NRTI
backbone
454 (8.7) 140 (7.8) 583 (7.2) 206 (7.8) 238 (4.0) 74 (4.9)
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period. It was only in 2013 that the WHO guidelines changed
to recommend an efavirenz-based regimens for all, including
women of childbearing age and pregnant women. Of note,
despite the WHO changes in 2013, all regions with the excep-
tion of North America, observed an increase in the proportion
of women initiating efavirenz-containing regimens from 2010
onwards compared to earlier time periods.
Protease inhibitor (PI) based first-line regimens were infre-
quent in both men and women in low-income settings. This is
in contrast to North America where PI containing first-line
therapy was used in 40% to 60% of men and women. This
occurred across all time periods and likely reflects local guide-
lines, broader formularies that include PIs, and less prohibitive
cost of PIs in a resource-rich setting.
The median CD4 count at ART initiation by sex was higher
in women compared with men across all time periods in low/
middle income Asia-Pacific, East Africa, Southern Africa, West
Africa, and the Caribbean, Central and South America. In the
remaining regions of Asia-Pacific high income and North Amer-
ica, the median CD4 count was higher in women compared to
men in at least two of the three time periods. Overall this is
consistent with other published data [18-22]. This may reflect
women presenting earlier (or alternatively men presenting
later), women being initiated earlier on treatment or starting
treatment earlier because of other sex specific indications
such as pregnancy or increased access to health services.
Women were significantly more likely to have a switch in
their first-line regimen compared to men in the Southern Afri-
can and East Africa cohorts (p < 0.001). This difference
remained even after restricting the analysis to women
>35 years at study entry as a strategy to account for switching
due to pregnancy (data not presented). Restricting to women
aged greater than 35 years is not an ideal way to account for
pregnancy events and could introduce other biases. Unfortu-
nately we did not have individual-level data on pregnancies and
therefore this was one possible way to answer the concern that
some treatment decisions are likely influenced by pregnancy.
Of note, this was only a sensitivity analysis and not part of the
main analysis. Our results were largely similar to the respective
figures representing the main analysis (Figures 1 and 2).
Table 1. (Continued)
Time period
First-line
ART regimen
2003 to 2005 2006 to 2009 2010 to 2014
Setting
Males
N (%)
Females
N(%)
Males
N (%)
Females
N(%)
Males
N (%)
Females
N(%)
Caribbean, Central
and South America
N = 22,040
EFV 1756 (63.7) 700 (37.9) 3599 (78.6) 1158 (36.9) 3382 (83.8) 1038 (47.9)
NVP 570 (20.7) 901 (48.8) 343 (7.5) 1569 (50.0) 128 (3.2) 759 (35.0)
PI 361 (13.1) 135 (7.3) 597 (13.0) 366 (11.7) 489 (12.1) 356 (16.4)
TDF 62 (2.3) 50 (2.7) 640 (14.0) 218 (7.0) 1642 (40.7) 1003 (46.3)
AZT/3TC 2261 (82.0) 1556 (84.2) 3321 (72.5) 2441 (77.8) 1941 (48.1) 1010 (46.6)
D4T/3TC 274 (9.9) 207 (11.2) 381 (8.3) 413 (13.2) 108 (2.7) 67 (3.1)
Other NRTI
backbone
182 (6.6) 70 (3.8) 264 (5.8) 105 (3.6) 351 (8.7) 93 (4.3)
% are column percentages (percentages from the total in the given time-period and gender).
EFV, Efavirenz; NVP, nevirapine; PI, protease inhibitor; TDF, tenofovir; 3TC, lamivudine; AZT, zidovudine; D4T, stavudine.
Table 2. Median CD4 count cells/lL (IQR) at ART initiation by sex and region over time
Time period
2003 to 2005 2006 to 2009 2010 to 2014
Setting Males Females Males Females Males Females
Asia/Pacific Low/low-middle
income settings
98 (47 to 174) 123 (52 to 203) 125 (55 to 209) 171 (82 to 241) 140 (45 to 272) 226 (101 to 326)
Asia/Pacific Upper to
middle/high-income
settings
97 (28 to 229) 113 (32 to 209) 99 (29 to 225) 127 (41 to 211) 206 (64 to 328) 175 (60 to 289)
Southern Africa 83 (19 to 174) 85 (19 to 170) 77 (15 to 180) 101 (18 to 193) 103 (19 to 216) 149 (27 to 257)
East Africa 90 (29 to 165) 117 (47 to 193) 117 (47 to 189) 140 (68 to 206) 157 (65 to 254) 198 (99 to 290)
West Africa 74 (12 to 182) 94 (14 to 208) 98 (20 to 208) 134 (25 to 257) 101 (18 to 236) 150 (25 to 282)
North America 209 (67 to 354) 244 (105 to 400) 261 (113 to 395) 276 (136 to 428) 349 (180 to 512) 324 (165 to 490)
Caribbean, Central
and South America
117 (43 to 222) 141 (52 to 234) 152 (55 to 259) 177 (85 to 267) 203 (73 to 322) 235 (117 to 331)
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Figure 1. Major change in antiretroviral regimen over time according to region and sex.
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Figure 2. Major interruption in antiretroviral regimen over time according to region and sex.
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Approximately 50% of women in Southern and East Africa
cohorts had switched by 8 years of follow-up; this contrasts
with the West Africa regional data, which showed no signifi-
cant difference according to sex. Similarly, Asia Pacific low/low
middle income sites reported no significant difference in rate
of switch in ART regimen according to sex. However, it is
striking that by 10 years of follow-up >75% of this cohort
(Asia Pacific low/lowmiddle income) had undergone a change in their
first-line regimen. Data from Asia Pacific upper middle/high income
sites demonstrated that switchingwasmore likely inmales compared
to females. This data set has a significant contribution from Australia
(17%) which comprises predominantly of men (90% of participant
data from Australia to IeDEA Asia-Pacific is male). Hence, if gender-
specific factors such as pregnancy are driving the earlier switch in
ARTregimen, then thismay explain inconsistent findings in this region
compared to the African counterparts. This finding from a high-
income setting in the Asia Pacific region was not a consistent finding
in other high-income settings. In the North American cohort, women
weremore likely to undergo a switch thanmen, suggesting socioeco-
nomic status of the region may not be a factor contributing to sex-
specific differences in changes to ART therapy.
Previous studies investigating factors associated with first-
line ART change have reported toxicity as the single most
important reason for change [23-25]. The probability of ther-
apy change at one year, has been reported approximating
25% [26], increasing to up to 80% by 6 years. [27]. Similarly,
reasons for treatment interruption (as opposed to switching)
have also been reported in studies to be more often due to
toxicity than failure [12]. Interestingly, in a study from Latin
America and the Caribbean, comprising of 35% females, efa-
virenz-based regimens were associated with a lower risk of
switching compared to nevirapine- and other non-NNRTI-
based regimens [8]. On one hand, this argues against concerns
regarding pregnancy and teratogenicity as the reason for switching
of first-line regimens in women, but may actually reflect the recog-
nized higher rates of toxicity from nevirapine-based regimens in
women compared with men. In a study by Monforte et al. [12], sex
was an independent factor associated with treatment interruption
for toxicity, with men 57% less likely than women to discontinue ART
because of toxicity. The findings in our study are similar in terms of
proportions of patients who undergo a treatment switch, although
unfortunately this study did not explore the reasons for switching.
Teasing out the reasons for switch (toxicity, pregnancy, drug interac-
tions or resistance) warrants further investigation and is essential to
our understanding of the possible differences between change and
treatment interruption as observed in our study according to sex.
Although routine HIV viral load testing may detect early
emerging drug resistance and lead to switching of ART regi-
men, the availability and frequency of this test across different
regions of the world remains variable. A Cochrane review [28]
evaluated the optimal monitoring strategy for guiding when to
switch ART for first-line treatment failure. Their conclusion
was that there was a substantial benefit in terms of mortality
and AIDS defining illness if immunological and clinical or viro-
logical monitoring was used versus clinical monitoring alone
[28]. Haas et al. recently examined the rate of switching from
first-line ART across 16 countries in sub-Saharan Africa. Only
3% of those followed up had switched to second-line ART;
change of ART was not only more common but also occurred
earlier with the use of targeted routine viral load testing [11].
It is unlikely that the differences reported in our study
between men and women in terms of switching is due to the
availability (or not) of viral load testing per region. It is
expected that viral load testing if available would be accessible
equally for men and women in a particular region and there-
fore switching in relation to availability of testing should be
equally distributed according to sex.
In general, the likelihood of a treatment interruption varied
according to sex and region. Treatment interruption was
more likely for males in Southern Africa, Asia-Pacific low-
and middle-income sites. In West Africa, there was no signifi-
cant difference according to sex but the data suggest that
90% of participants had no treatment interruption after 10
years of follow-up which is significantly higher than the other
African cohorts. The other regions where there were no signifi-
cant differences in the rate of treatment interruption according to
sex when adjusted for age and CD4 count at ART initiation, first-line
NRTI backbone (AZT vs TDF vs D4T), type of anchor agent (NVP vs
EFV vs PI) and mode of exposure included high-income Asia Pacific
sites and Caribbean Central/South America. Only in North America
were womenmore likely to have a treatment interruption. An impor-
tant consideration in interpreting this finding is to ask if it is due to
data capture, or due to gender-specific issues and how these may
vary across the different regions sufficiently to explain the inconsis-
tencies.
A major strength of this study is that it analysed a large
cohort consortia from a diverse range of settings and regions,
but a significant limitation of this paper is the inability to
account for important factors unique to women such as preg-
nancy which are likely to impact on switching and treatment
interruption. Women already initiated on ART may change
their treatment when they find out they are pregnant. Simi-
larly, women may interrupt their therapy post partum either
due to patient or programmatic factors (Option B vs. B+). In
2015, the WHO recommended lifelong ART for all pregnant
and breastfeeding women regardless of CD4 count. Much of
the data in our study included women prior to 2015.
In summary, we have demonstrated that there are sex and
regional variations in choice of initial ART, switching and treat-
ment interruption. Given the massive scale up of HIV treatment
that has occurred over the last decade, and the anticipated
expansion in ART services in the next decade, it is essential to
understand the drivers behind these differences. Drivers of
treatment change such as pregnancy, toxicity, drug interactions
and resistance need to be considered in more detail when
exploring reasons for ART change or interruption, and in particu-
lar need to be compared between men and women.
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